These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36001445)

  • 1. Breaking Down the Breakpoints: Rationale for the 2022 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Enterobacterales.
    Tamma PD; Harris PNA; Mathers AJ; Wenzler E; Humphries RM
    Clin Infect Dis; 2023 Nov; 77(11):1585-1590. PubMed ID: 36001445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amoxicillin-clavulanate Breakpoints Against Enterobacterales: Rationale for Revision by the Clinical and Laboratory Standards Institute.
    Narayanan N; Mathers AJ; Wenzler E; Moore NM; Giske CG; Mendes RE; Edelstein PH
    Clin Infect Dis; 2024 Apr; ():. PubMed ID: 38626241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Multicenter Comparison of Carbapenem-Nonsusceptible Enterobacterales and Pseudomonas aeruginosa Rates in the US (2016 to 2020): Facility-Reported Rates versus Rates Based on Updated Clinical Laboratory and Standards Institute Breakpoints.
    Gupta V; Yu KC; Pogue JM; Watts JA; Clancy CJ
    Microbiol Spectr; 2022 Jun; 10(3):e0115822. PubMed ID: 35638777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Piperacillin-Tazobactam Testing against
    Manuel C; Maynard R; Abbott A; Adams K; Alby K; Sweeney A; Dien Bard J; Flores II; Rekasius V; Harrington A; Kidd TS; Mathers AJ; Tekle T; Simner PJ; Humphries RM
    J Clin Microbiol; 2023 Feb; 61(2):e0161722. PubMed ID: 36719243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of
    García-Fernández S; Bala Y; Armstrong T; García-Castillo M; Burnham CA; Wallace MA; Hardy D; Zambardi G; Cantón R
    J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31597745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible impact of revisions in disc diffusion breakpoints for aminoglycosides and piperacillin/tazobactam in the 33rd edition of CLSI M100 document on clinical reporting and use in Indian settings with low susceptibility.
    Aggarwal P; Saxena S; Nagi N
    Indian J Med Microbiol; 2024; 49():100602. PubMed ID: 38697481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disk Correlates for Revised Clinical and Laboratory Standards Institute
    Humphries R; Tamma PD; Mathers AJ
    J Clin Microbiol; 2022 May; 60(5):e0024322. PubMed ID: 35443782
    [No Abstract]   [Full Text] [Related]  

  • 8.
    Karlowsky JA; Lob SH; Siddiqui F; Akrich B; DeRyke CA; Young K; Motyl MR; Hawser SP; Sahm DF
    J Med Microbiol; 2023 Feb; 72(2):. PubMed ID: 36763081
    [No Abstract]   [Full Text] [Related]  

  • 9. Revision of fluoroquinolone breakpoints used for interpretation of antimicrobial susceptibility testing of canine bacterial isolates.
    Papich MG; Gunnett LA; Lubbers BV
    Am J Vet Res; 2023 Nov; 84(11):. PubMed ID: 37673214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for Updating Piperacillin-Tazobactam Breakpoints.
    Bobenchik AM
    J Clin Microbiol; 2023 Apr; 61(4):e0004223. PubMed ID: 36920195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Setting Antimicrobial Susceptibility Testing Breakpoints: A Primer for Pediatric Infectious Diseases Specialists on the Clinical and Laboratory Standards Institute Approach.
    Pierce VM; Mathers AJ
    J Pediatric Infect Dis Soc; 2022 Feb; 11(2):73-80. PubMed ID: 34888640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria.
    Asín E; Isla A; Canut A; Rodríguez Gascón A
    Int J Antimicrob Agents; 2012 Oct; 40(4):313-22. PubMed ID: 22921422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment.
    DeRyke CA; Kuti JL; Nicolau DP
    Diagn Microbiol Infect Dis; 2007 Jul; 58(3):337-44. PubMed ID: 17350206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introducing the new face of CLSI M100 in 2023: An explanatory review.
    Rai S; Dash D; Agarwal N
    Indian J Med Microbiol; 2023; 46():100432. PubMed ID: 37945125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piperacillin/tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing.
    Lodise TP; Bhavnani SM; Ambrose PG; Sader HS; Andes DR; Pogue JM
    Clin Infect Dis; 2024 Jun; ():. PubMed ID: 38902929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperacillin/Tazobactam Dose Optimization in the Setting of Piperacillin/Tazobactam-susceptible, Carbapenem-resistant Pseudomonas aeruginosa: Time to Reconsider Susceptible Dose Dependent.
    Gill CM; Nicolau DP;
    Clin Ther; 2023 Jan; 45(1):72-77. PubMed ID: 36593150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Daptomycin Susceptibility Breakpoints for Enterococcus faecium and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute.
    Satlin MJ; Nicolau DP; Humphries RM; Kuti JL; Campeau SA; Lewis Ii JS; Weinstein MP; Jorgensen JH
    Clin Infect Dis; 2020 Mar; 70(6):1240-1246. PubMed ID: 31504338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa.
    Cojutti PG; Morandin E; Baraldo M; Pea F
    Int J Antimicrob Agents; 2021 Oct; 58(4):106408. PubMed ID: 34314808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
    Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
    J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.